{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-055201","form_type":"8-K","ticker":"IDXX","cik":"0000874716","company_name":"IDEXX LABORATORIES INC /DE","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.239033+00:00","generated_at":"2026-06-03T03:40:17.344581+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"IDEXX Q1 revenue $964M (+7%), EPS $2.81; cuts 2024 revenue/EPS guidance on FX and visit slowdown","bullets":["Q1 revenue $964M (+7% as reported and organic); EPS $2.81 (+10% reported, +9% comparable).","CAG Diagnostics recurring revenue grew 7% as reported and organic; global premium instrument installed base up 11% YoY.","FY2024 revenue guidance lowered to $3,895M-$3,965M (prior $3,930M-$4,040M); EPS guidance lowered to $10.82-$11.20.","Guidance cut reflects ~$35M FX headwind and reduction of 1% from high end of organic growth range due to US clinical visit moderation.","Gross margin improved 120bps to 61.5%; operating margin contracted 10bps to 31.0% due to lapping a Q1 2023 customer contract resolution payment."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-055201","json":"https://secwatch.observer/filing/0001104659-24-055201.json","markdown":"https://secwatch.observer/filing/0001104659-24-055201.md","text":"https://secwatch.observer/filing/0001104659-24-055201.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874716/000110465924055201/0001104659-24-055201-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874716/000110465924055201/tm2413183d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T03:40:17.344581+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fb4e1c679245d88ae918f1157165790cd2440802","claim":"IDEXX LABORATORIES INC /DE reported the quarter ended March 31, 2024 results: revenue $964 million, EPS $2.81. Guidance reaffirmed.","evidence_excerpt":"Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results. First Quarter Results The Company reports revenues of $964 million for the first quarter of 2024, an increase of 7% as reported and organic, driven by Companion Animal Group (\"CAG\") growth of 7% as reported and organic, and Water revenue growth","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/874716/000110465924055201/0001104659-24-055201-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$964 million"},{"label":"EPS","value":"$2.81"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}